Circassia Pharmaceuticals ( (GB:NIOX) ) has issued an update.
NIOX Group PLC reported a 14% revenue growth to £41.8 million for the year ended 31 December 2024, with a 21% increase in adjusted EBITDA to £13.8 million. The company announced a proposal from Keensight Capital for a potential acquisition, though discussions are preliminary. Operationally, NIOX saw a 19% increase in NIOX® FeNO tests sold and is on track to launch the NIOX PRO® device in Q4 2025. The company is expanding its manufacturing capacity and distributor network, with plans to return 80% of free cash flow to shareholders, reflecting strong financial health and strategic growth initiatives.
More about Circassia Pharmaceuticals
NIOX Group PLC is a medical device company specializing in point-of-care asthma diagnosis, monitoring, and management. The company is engaged in the design, development, and commercialization of devices for measuring FeNO, a biomarker for asthma, with their leading product being the NIOX VERO®. They operate through direct sales and a distributor network in over 50 countries.
YTD Price Performance: 20.32%
Average Trading Volume: 953,364
Technical Sentiment Signal: Sell
Current Market Cap: £301.2M
See more data about NIOX stock on TipRanks’ Stock Analysis page.